Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Phase I study of the preventive effect of Kampo medicine on oxaliplatin-induced peripheral neurotoxicity

ABSTRACT: Interventions: During XELOX regimen, Kampo medicine is administered as follows: Level 1(TJ-18 7.5g, TJ-3023 0g), Level 2(TJ-18 7.5g, TJ-3023 1.5g), Level 3(TJ-18 7.5g, TJ-3023 3.0g) Primary outcome(s): Decision of DLT, MTD, RD of Kampo medicine (TJ-3023, TJ-18) Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2631410 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Preventive effect of Bushimatsu and Keishikajubutou on peripheral neurotoxicity of Oxaliplatin(L-OHP) therapy: a phase II clinical study.

Project description:Interventions: administration of keishi kajutubu tou (TJ - 18) + Bushi matsu (TJ - 3023) Primary outcome(s): Safety and efficacy of Keishi Kamisukutou (TJ - 18) + bushi-matsu (TJ - 3023) for oxaliplatin-induced peripheral neuropathy Study Design: Single arm Non-randomized

| 2646318 | ecrin-mdr-crc

Preventive effect of Bushimatsu and Keishikajutsubuto on peripheral neurotoxicity of Oxaliplatin(L-OHP) therapy: a phase II clinical study.

Project description:Interventions: Administration of Keishikajutsubuto (TJ - 18) + Bushi matsu (TJ - 3023) Primary outcome(s): dose limiting toxicity, maximum tolerated dose, recommended Dose Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose

| 2615226 | ecrin-mdr-crc

Preventive Effect of Goshajinkigan on Peripheral Neurotoxicity of FOLFOX Therapy :A Placebo-controlled Double-blind Randomized Phase III Study

Project description:Interventions: Goshajinkigan 7.5g/day, 12 course + mFOLFOX6 12 course Placebo 7.5g/day, 12 course + mFOLFOX6 12 course Primary outcome(s): TimeToGrade2+ (CTCAE v4.0) Neuropathy; TTN Study Design: Parallel Randomized

| 2619732 | ecrin-mdr-crc

IGNITE: Genomic Medicine Implementation - The Personalized Medicine Program

Project description:IGNITE: Genomic Medicine Implementation - The Personalized Medicine Program

| PRJNA606620 | ENA

IGNITE: Genomic Medicine Implementation - The Personalized Medicine Program

Project description:IGNITE: Genomic Medicine Implementation - The Personalized Medicine Program

| PRJNA606621 | ENA

Expression data of 8 healthy people and 8 patients with coronary heart disease before and after 8 weeks treatment with Danlou tablets

Project description:The Danlou Tablets (DLT), a patented medicine, has been widely used to treat coronary heart disease (CHD) in China for several decades. Though the anti-inflammatory and anti-oxidation effect has been preliminarily proposed as one of the potential mechanisms of DLT for CHD treatment, the underlying mechanisms remain elusive. We use microarray to explain the genome changes of patients with coronary heart disease and patients with coronary heart disease after treatment with Danlou tablets, so as to explore the potential mechanism of treating diseases with traditional Chinese medicine.

2023-06-14 | GSE179789 | GEO

traditional chinese medicine

Project description:traditional chinese medicine Targeted loci

| PRJNA796441 | ENA

A Japanese herbal medicine, Hochuekkito (TJ-41), has anti-inflammatory effects on the COPD mouse model

Project description:We assessed the anti-inflammatory and systemic effects of TJ-41 on the COPD mouse model induced by porcine pancreatic elastase (PPE) and lipopolysaccharide (LPS).

2024-05-15 | GSE239537 | GEO

Differences in serum proteins in traditional Chinese medicine constitutional population: analysis and verification

Project description:Using high-throughput antibody microarray, through cross-sectional sample detection and verification of samples that had undergone physical changes over time, it was found that people with balanced constitution and dampness constitution in Chinese medicine showed differences in serum protein expression. The differences were expressed as the level changes of 19 proteins such as Dectin-2, Siglec-7, AIF and TACI. The research results provided the basis for the scientific expression of traditional Chinese medicine (TCM) constitution.

2019-11-22 | GSE140769 | GEO

Preventive effect of shakuyaku-kanzo-to on neurotoxicity of FOLFOX plus bevacizumab for patients with metastatic colorectal cancer: a prospective phase II study

Project description:Interventions: Patients receive FOLFOX4 plus bevacizumab or modified FOLFOX6 plus bevacizumab and take shakuyaku-kanzo-to (7.5g/day) orally every day during FOLFOX plus bevacizumab treatment. Primary outcome(s): Neurotoxicity frequency of accumulation dose 500mg/m2 of oxaliplatin Study Design: Single arm Non-randomized

| 2617341 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data